Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.…
Perspective Therapeutics: Q3 Earnings Snapshot
Perspective Therapeutics (NYSEAMERICAN: CATX) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 163 employees.
The shares were at 0.7538 USD on 20 November 2026, down 72.4% over 52 weeks. Its 52-week range is 0.7252 USD to 6.160 USD: the price is 87.8% below the high and 3.9% above the low.
Its market capitalisation is 91.03M USD.
Perspective Therapeutics reports return on equity of -49.8% and revenue down 90.4% year over year.
It holds more cash than debt, a net cash position of 198.02M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 15 March 2027.